Epidermal growth factor receptor family, Janus kinase 3, and Src family kinases (EGFR/JAK3/SFK)

The target group comprising the Epidermal Growth Factor Receptor (EGFR) family, Janus kinase 3 (JAK3), and Src family kinases (SFKs) represents a broad spectrum of tyrosine kinases involved in critical cellular signaling pathways (UniProt: P00533, P52333, P12931). The EGFR family (ErbB1-4) consists of receptor tyrosine kinases that regulate epithelial cell growth and are frequently mutated or overexpressed in various cancers, such as non-small cell lung cancer and breast cancer (PubMed: 25223553). JAK3 is a non-receptor tyrosine kinase predominantly expressed in hematopoietic cells, where it mediates signaling from cytokine receptors containing the common gamma chain, making it a key target for immunosuppression and hematologic malignancies (PubMed: 24854257). Src family kinases are non-receptor kinases that integrate signals from various surface receptors to regulate processes like cell adhesion, migration, and survival, often contributing to tumor progression and metastasis (PubMed: 15184872). While drugs like erlotinib (EGFR), tofacitinib (JAK), and dasatinib (Src) target these proteins individually or in small subsets, simultaneous inhibition of these pathways is often explored to overcome drug resistance in oncology. These kinases collectively govern the transition from external stimuli to intracellular responses, and their dysregulation is a hallmark of many proliferative and inflammatory disorders. Therapeutic strategies targeting these kinases often involve small-molecule inhibitors that compete with ATP for binding to the catalytic domain. Monitoring for specific mutations and expression levels is crucial for patient selection and predicting treatment efficacy.

Other names

ErbB familyJAK3SFKsTyrosine-protein kinase JAK3Proto-oncogene tyrosine-protein kinase SrcHER family

Inhibition of the kinase domain by competing with adenosine triphosphate (ATP) for binding, thereby preventing the phosphorylation of tyrosine residues on downstream signaling proteins and halting intracellular cascades such as the MAPK/ERK and PI3K/Akt pathways.